跳至主要内容
临床试验/NCT02516306
NCT02516306已完成1 期

A Phase 1/2 Prospective, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution, in Improving Distance Corrected Near Vision in Subjects With Presbyopia

Encore Vision, Inc.4 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2015年9月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
75
试验地点
4
主要终点
Ocular Comfort Assessment Following Instillation at Baseline and the Day Prior to Each Study Visit

研究概览

简要总结

The purpose of this study is to determine whether EV06 Ophthalmic Solution is safe and effective in improving distance corrected near vision in people who have presbyopia.

详细描述

Study subjects who were eligible for enrollment and had provided written informed consent were randomized in a 2:1 ratio to use of either EV06 Ophthalmic Solution or Placebo Ophthalmic Solution. For the first 7 days of study product administration (Period 1: Days 1-7), subjects applied 1 drop of their assigned study product to one eye twice per day. For the next 84 days (Period 2: Days 8 - 91), if there were no unanticipated and no significant adverse events observed in the treated eye, subjects applied 1 drop of their assigned study product to both eyes twice per day.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
45 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 45 to 55 years of age
  • Distance Corrected Near Visual Acuity worse than 20/40
  • Best Corrected Distance Visual Acuity of 20/20 or better in each eye
  • Willing and able to sign consent, following study instructions

排除标准

  • Certain pupillary conditions
  • Significant astigmatism, glaucoma, diabetes, cataracts, eye surgery, ocular trauma or accommodative issues
  • contact lens wear within 3 days prior to and for duration of study
  • use of prohibited medications
  • participation in a clinical study within 30 days prior

研究组 & 干预措施

EV06 Ophthalmic Solution

Experimental

EV06 Ophthalmic Solution: Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.

干预措施: EV06 Ophthalmic Solution (Drug)

Placebo Ophthalmic Solution

Placebo Comparator

Placebo Ophthalmic Solution (EV06 vehicle): Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.

干预措施: Placebo Ophthalmic Solution (Drug)

结局指标

主要结局

Ocular Comfort Assessment Following Instillation at Baseline and the Day Prior to Each Study Visit

时间窗: Baseline, Day 7, Day 14, Day 30, Day 60, Day 90

Ocular comfort was assessed at Baseline (Day 1) and following the last dose on the day prior to each office visit. Comfort was assessed by each subject marking a visual analog scale labeled "0" (Very Comfortable), "5" (Comfortable) and "10" (Very Uncomfortable) immediately following instillation of their assigned study product to one eye (Baseline) or both eyes (Days 8 - 91). A small number indicated better comfort. No formal inferential statistics hypotheses were tested.

次要结局

未报告次要终点

研究者

发起方
Encore Vision, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验